TScan Therapeutics, Inc. Board of Directors

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Mr. Ray Lockard M.B.A.

Mr. Ray Lockard M.B.A.

Senior Vice President & Head of Quality

Dr. Justin McCue Ph.D.

Dr. Justin McCue Ph.D.

Chief Technology Officer

Mr. Tomasz Kula Ph.D.

Mr. Tomasz Kula Ph.D.

Co-Founder & Member of Advisory Board

Dr. Shrikanta Chattopadhyay M.D.

Dr. Shrikanta Chattopadhyay M.D.

Senior VP & Head of Translational Medicine

Ms. Ann Hargraves

Ms. Ann Hargraves

Senior Vice President of Human Resources

Dr. Stephen J. Elledge Ph.D.

Dr. Stephen J. Elledge Ph.D.

Co-Founder & Chairman of Scientific Advisory Board

Dr. Zoran Zdraveski J.D., Ph.D.

Dr. Zoran Zdraveski J.D., Ph.D.

Chief Legal & Strategy Officer and Company Secretary

Mr. Jim Murray

Mr. Jim Murray

Senior VP & Head of Development Operations

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.